State Street reports 5.1% stake in Vanda Pharmaceuticals

Rhea-AI Filing Summary

State Street Corporation reported beneficial ownership of 3,015,562 shares (5.1%) of Vanda Pharmaceuticals as of 03/31/2026 on a Schedule 13G. The filing shows shared voting power of 2,935,448 shares and shared dispositive power of 3,015,562 shares, with holdings held on behalf of multiple State Street advisory entities.

Insights

Institutional Ownership Analyst

Large passive position disclosed by State Street at 5.1%.

State Street Corporation reports 3,015,562 shares beneficially owned (5.1%) as of 03/31/2026, with shared voting power of 2,935,448 shares. The filing is a Schedule 13G, which typically reflects passive investment management rather than an active acquisition.

The disclosure names affiliated managers such as SSGA Funds Management, Inc. and others; cash‑flow treatment and any plans for disposition are not stated in the excerpt. Subsequent filings would show any material change in ownership or voting intent.

Corporate Governance Specialist

Voting and dispositive splits signal agency-managed holdings.

The schedule lists shared voting power (2,935,448 shares) and shared dispositive power (3,015,562 shares), indicating holdings are managed across State Street investment vehicles. Item 6 is answered "Not applicable" for third‑party rights to proceeds, per the excerpt.

Because the filing is a 13G, the position is presented as passive; any change to active intent would require an amended filing under the applicable rules.

Key Figures

Report date (ownership as of): 03/31/2026 Beneficial ownership: 3,015,562 shares Percent of class: 5.1% +2 more

5 metrics

Report date (ownership as of) 03/31/2026 Ownership reporting date on Schedule 13G

Beneficial ownership 3,015,562 shares Amount beneficially owned reported by State Street

Percent of class 5.1% Percentage of Vanda Pharmaceuticals common stock

Shared voting power 2,935,448 shares Number of shares with shared power to vote

CUSIP 921659108 Identifier for Vanda Pharmaceuticals common stock

Key Terms

Schedule 13G, Beneficially owned, Shared dispositive power

3 terms

Schedule 13G regulatory

"Schedule 13G filing reporting passive beneficial ownership (first line)"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Beneficially owned financial

"Amount beneficially owned: 3015562.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Shared dispositive power regulatory

"Shared power to dispose or to direct the disposition of: 3,015,562"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does State Street (VNDA) report on Schedule 13G?

State Street reports beneficial ownership of 3,015,562 shares, representing 5.1% of Vanda Pharmaceuticals as of 03/31/2026. The filing lists shared voting power of 2,935,448 shares and identifies several State Street advisory subsidiaries as holders.

Does the Schedule 13G indicate State Street plans to control Vanda Pharmaceuticals (VNDA)?

No explicit control intent is stated; the filing is a Schedule 13G, which typically indicates a passive position. The disclosure shows shared voting power and does not assert active control or a change in intent in the provided excerpt.

Which State Street entities are named as holders in the VNDA filing?

The filing identifies affiliated managers including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company as relevant subsidiaries involved in the reported holdings.

When was the Schedule 13G for VNDA signed and by whom?

The excerpt shows the report signed by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer, with a signature date of 05/12/2026, while the ownership is reported as of 03/31/2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 12:18 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

VANDA PHARMACEUTICALS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

921659108

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 921659108

1

Names of Reporting Persons

STATE STREET CORPORATION

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,935,448.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,015,562.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,015,562.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: VANDA PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 2200 PENNSYLVANIA AVENUE NW SUITE 300E, WASHINGTON, DISTRICT OF COLUMBIA, 20037
Item 2.
(a)	Name of person filing: STATE STREET CORPORATION;
(b)	Address or principal business office or, if none, residence: ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
(c)	Citizenship: MA
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP Number(s): 921659108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3015562.00
(b)	Percent of class: 5.1 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 2,935,448
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,015,562
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. NOT APPLICABLE
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. NOT APPLICABLE
Item 9.	Notice of Dissolution of Group.
	Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. NOT APPLICABLE

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

STATE STREET CORPORATION

Signature:	ELIZABETH SCHAEFER
Name/Title:	SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
Date:	05/12/2026